Phosphorylation of Bcl-2 in G2/M Phase-arrested Cells following Photodynamic Therapy with Hypericin Involves a CDK1-mediated Signal and Delays the Onset of Apoptosis*

The role of Bcl-2 in photodynamic therapy (PDT) is controversial, and some photosensitizers have been shown to induce Bcl-2 degradation with loss of its protective function. Hypericin is a naturally occurring photosensitizer with promising properties for the PDT of cancer. Here we show that, in HeLa cells, photoactivated hypericin does not cause Bcl-2 degradation but induces Bcl-2 phosphorylation in a dose- and time-dependent manner. Bcl-2 phosphorylation is induced by sublethal PDT doses; increasing the photodynamic stress promptly leads to apoptosis, during which Bcl-2 is neither phosphorylated nor degraded. Bcl-2 phosphorylation involves mitochondrial Bcl-2 and correlates with the kinetics of a G2/M cell cycle arrest, preceding apoptosis. The co-localization of hypericin with α-tubulin and the aberrant mitotic spindles observed following sublethal PDT doses suggest that photodamage to the microtubule network provokes the G2/M phase arrest. PDT-induced Bcl-2 phosphorylation is not altered by either the overexpression or inhibition of p38 mitogen-activated protein kinase (p38 MAPK) and c-Jun NH2-terminal protein kinase 1 (JNK1) nor by inhibiting the extracellular signal-regulated kinases (ERKs) or protein kinase C. By contrast, Bcl-2 phosphorylation is selectively suppressed by the cyclin-dependent protein kinase (CDK)-inhibitor roscovitine, completely blocked by the protein synthesis inhibitor cycloheximide and enhanced by the overexpression of CDK1, suggesting a role for this pathway. However, in an in vitro kinase assay, active CDK1/cyclin B1 complex failed to phosphorylate immunoprecipitated Bcl-2, suggesting that this protein kinase may not directly modify Bcl-2. Mutation of serine-70 to alanine in Bcl-2 abolishes PDT-induced phosphorylation and restores the caspase-3 activation to the same levels of the vector-transfected cells, indicating that Bcl-2 phosphorylation may be a signal to delay apoptosis in G2/M phase-arrested cells.

[1]  M. Blagosklonny.  Unwinding the loop of Bcl-2 phosphorylation , 2001, Leukemia.

[2]  C. M. Allen,et al.  Photodynamic therapeutics: basic principles and clinical applications. , 1999, Drug discovery today.

[3]  C. Croce,et al.  Inactivation of Bcl-2 by phosphorylation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Kessel,et al.  Enhanced apoptotic response to photodynamic therapy after bcl-2 transfection. , 1999, Cancer research.

[5]  B. McManus,et al.  Bcl-2 overexpression blocks caspase activation and downstream apoptotic events instigated by photodynamic therapy , 1999, British Journal of Cancer.

[6]  V. Rialet,et al.  A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates. , 1991, Anticancer research.

[7]  Maria Torcia,et al.  Nerve Growth Factor Inhibits Apoptosis in Memory B Lymphocytes via Inactivation of p38 MAPK, Prevention of Bcl-2 Phosphorylation, and Cytochrome c Release* , 2001, The Journal of Biological Chemistry.

[8]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[9]  L. Zon,et al.  Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1 , 1994, Nature.

[10]  R. Perez-soler,et al.  Phosphorylation of Bcl-2 Is a Marker of M Phase Events and Not a Determinant of Apoptosis* , 1998, The Journal of Biological Chemistry.

[11]  P. Agostinis,et al.  Differential stimulation of ERK and JNK activities by ultraviolet B irradiation and epidermal growth factor in human keratinocytes. , 1997, The Journal of investigative dermatology.

[12]  Kazuhito Yamamoto,et al.  BCL-2 Is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway Normally Activated at G2/M , 1999, Molecular and Cellular Biology.

[13]  T. Chambers,et al.  Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistent forms of normal fluctuations at G2-M1. , 2000, Cancer research.

[14]  G L Snyder,et al.  Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? , 2001, The Journal of biological chemistry.

[15]  B. Hill,et al.  Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. , 2001, Molecular pharmacology.

[16]  P. Agostinis,et al.  Cellular Photodestruction Induced by Hypericin in AY-27 Rat Bladder Carcinoma Cells , 2001, Photochemistry and photobiology.

[17]  John Calvin Reed,et al.  Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. , 1993, Cancer research.

[18]  J. Piette,et al.  Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization , 2001, Oncogene.

[19]  L. Meijer,et al.  cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF , 1988, Cell.

[20]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[21]  J C Reed,et al.  Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1. , 2001, Neoplasia.

[22]  P. G. Tyler,et al.  Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. , 1994, The Journal of biological chemistry.

[23]  N. Lawrence,et al.  Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle , 1998, Medicinal research reviews.

[24]  M. Agarwal,et al.  The Induction of Partial Resistance to Photodynamic Therapy by the Protooncogene BCL‐2 , 1996, Photochemistry and photobiology.

[25]  W. May,et al.  Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Moor,et al.  Signaling pathways in cell death and survival after photodynamic therapy. , 2000, Journal of photochemistry and photobiology. B, Biology.

[27]  N. Oleinick,et al.  The photobiology of photodynamic therapy: cellular targets and mechanisms. , 1998, Radiation research.

[28]  T. Fojo,et al.  Molecular effects of paclitaxel: Myths and reality (a critical review) , 1999, International journal of cancer.

[29]  S. Haldar,et al.  Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. , 1998, International journal of oncology.

[30]  B. Zhivotovsky,et al.  All along the watchtower: on the regulation of apoptosis regulators , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  K. Lu,et al.  Phosphorylation-dependent prolyl isomerization: a novel signaling regulatory mechanism , 1999, Cellular and Molecular Life Sciences CMLS.

[32]  Fengqin Gao,et al.  Novel Role for JNK as a Stress-activated Bcl2 Kinase* , 2001, The Journal of Biological Chemistry.

[33]  S. Kornblau,et al.  Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. , 2000, Journal of the National Cancer Institute. Monographs.

[34]  B. Gabrielli,et al.  Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events. , 2000, Experimental cell research.

[35]  D. Kessel,et al.  Evidence that bcl-2 is the Target of Three Photosensitizers that Induce a Rapid Apoptotic Response¶ , 2001, Photochemistry and photobiology.

[36]  P. Vandenabeele,et al.  Hypericin‐induced photosensitization of HeLa cells leads to apoptosis or necrosis , 1998, FEBS letters.

[37]  J. M. Adams,et al.  Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. , 1996, Oncogene.

[38]  T. Fojo,et al.  Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. , 1997, Cancer research.

[39]  H. Mukhtar,et al.  [32] Mechanism of photodynamic therapy-induced cell death , 2000 .

[40]  W. Merlevede,et al.  Differential cytotoxic effects induced after photosensitization by hypericin. , 1997, Journal of photochemistry and photobiology. B, Biology.

[41]  P. Petit,et al.  Over‐expression of Bcl‐2 does not protect cells from hypericin photo‐induced mitochondrial membrane depolarization, but delays subsequent events in the apoptotic pathway , 1999, FEBS letters.

[42]  N. Ahn,et al.  Signal transduction through MAP kinase cascades. , 1998, Advances in cancer research.

[43]  A. Strasser,et al.  The Bcl-2 family and cell death regulation. , 1998, Current opinion in genetics & development.

[44]  C. Croce,et al.  Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. , 1996, Cancer research.

[45]  F. Cozzolino,et al.  NGF withdrawal induces apoptosis in CESS B cell line through p38 MAPK activation and Bcl-2 phosphorylation. , 2000, Biochemical and biophysical research communications.

[46]  S. Leach,et al.  Mitotic Phosphorylation of Bcl-2 during Normal Cell Cycle Progression and Taxol-induced Growth Arrest* , 1998, The Journal of Biological Chemistry.

[47]  R. K Srivastava,et al.  Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C. Rudin,et al.  Bcl-xL is phosphorylated in malignant cells following microtubule disruption. , 1998, Cancer research.

[49]  J. C. Clemens,et al.  Expression, purification, crystallization, and biochemical characterization of a recombinant protein phosphatase. , 1993, The Journal of biological chemistry.

[50]  P Wadsworth,et al.  Taxol suppresses dynamics of individual microtubules in living human tumor cells. , 1999, Molecular biology of the cell.

[51]  Á. Villanueva,et al.  Photodynamic damage to HeLa cell microtubules induced by thiazine dyes , 1996, Cancer Chemotherapy and Pharmacology.

[52]  M. Horiuchi,et al.  Angiotensin Type 2 Receptor Dephosphorylates Bcl-2 by Activating Mitogen-activated Protein Kinase Phosphatase-1 and Induces Apoptosis* , 1997, The Journal of Biological Chemistry.

[53]  W. May,et al.  A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis* , 1998, The Journal of Biological Chemistry.

[54]  M. Dorée,et al.  p34cdc2 is located in both nucleus and cytoplasm; part is centrosomally associated at G2/M and enters vesicles at anaphase. , 1989, The EMBO journal.

[55]  M. Ewen,et al.  Bcl-2 Retards Cell Cycle Entry through p27Kip1, pRB Relative p130, and Altered E2F Regulation , 2000, Molecular and Cellular Biology.

[56]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[57]  A. Strasser,et al.  The anti‐apoptosis function of Bcl‐2 can be genetically separated from its inhibitory effect on cell cycle entry , 1997, The EMBO journal.

[58]  H. Pass,et al.  Photodynamic therapy in oncology: mechanisms and clinical use. , 1993, Journal of the National Cancer Institute.

[59]  W. May,et al.  Bcl-2 Phosphorylation Required for Anti-apoptosis Function* , 1997, The Journal of Biological Chemistry.

[60]  P. Vandenabeele,et al.  The Activation of the c-Jun N-terminal Kinase and p38 Mitogen-activated Protein Kinase Signaling Pathways Protects HeLa Cells from Apoptosis Following Photodynamic Therapy with Hypericin* , 1999, The Journal of Biological Chemistry.

[61]  C. Croce,et al.  Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. , 1998, Cancer research.

[62]  M. Muda,et al.  Bcl-2 Undergoes Phosphorylation by c-Jun N-terminal Kinase/Stress-activated Protein Kinases in the Presence of the Constitutively Active GTP-binding Protein Rac1* , 1997, The Journal of Biological Chemistry.

[63]  Y. Furukawa,et al.  Phosphorylation of Bcl-2 Protein by CDC2 Kinase during G2/M Phases and Its Role in Cell Cycle Regulation* , 2000, The Journal of Biological Chemistry.

[64]  S. Korsmeyer,et al.  Involvement of Microtubules in the Regulation of Bcl2 Phosphorylation and Apoptosis through Cyclic AMP-Dependent Protein Kinase , 1998, Molecular and Cellular Biology.

[65]  J Moan,et al.  Lysosomes and Microtubules as Targets for Photochemotherapy of Cancer , 1997, Photochemistry and photobiology.

[66]  A. Krainer,et al.  NIPP1-mediated Interaction of Protein Phosphatase-1 with CDC5L, a Regulator of Pre-mRNA Splicing and Mitotic Entry* , 2000, The Journal of Biological Chemistry.

[67]  S. Haldar,et al.  Regulation of Bcl2 phosphorylation by stress response kinase pathway. , 2000, International journal of oncology.

[68]  Cheryl Brantley-Finley,et al.  Vinblastine-induced Phosphorylation of Bcl-2 and Bcl-XL Is Mediated by JNK and Occurs in Parallel with Inactivation of the Raf-1/MEK/ERK Cascade* , 2000, The Journal of Biological Chemistry.

[69]  H. Mukhtar,et al.  Involvement of Bcl-2 and Bax in Photodynamic Therapy-mediated Apoptosis , 2001, The Journal of Biological Chemistry.

[70]  T. Hunter,et al.  Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport , 1991, The Journal of cell biology.

[71]  P. Agostinis,et al.  Hypericin in cancer treatment: more light on the way. , 2002, The international journal of biochemistry & cell biology.